At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 91 enrolled
Drug / intervention
Quetiapine-XRdrug
Likely dose
Quetiapine-XR 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cardiovascular Biomarkers During Quetiapine Treatment of Depression
In Brief
A Phase 4 clinical trial evaluating Quetiapine-XR for Depression and Anxiety. Completed, enrolled 91 participants across 1 site.
Detailed Summary
No suitable treatment has been identified to reverse and ideally prevent, the cardiovascular disease risk associated with depression and anxiety. The purpose of this study is to determine if quetiapine treatment of depression can reverse the signs of arterial stiffening that often occurs in depression and anxiety, and which are believed to be risk factors for future heart disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression, Anxiety
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
First PostedAug 2009
Primary CompletionOct 2011
TodayJul 2026
First PostedAug 4, 2009
Enrollment StartJul 1, 2009
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.9 years ago
Interventions
Quetiapine-XRdrug
Quetiapine-XR (Seroquel-XR) 50-300mg daily for 12 weeks.